Comparing the Long-term Cost-effectiveness of Repaglinide Plus Metformin Versus Nateglinide Plus Metformin in Type 2 Diabetes Patients with Inadequate Glycaemic Control: An Application of the CORE Diabetes Model in Type 2 Diabetes

Author： Palmer Andrew J.   Roze Stéphane   Lammert Morten   Valentine William J.   Minshall Michael E.   Nicklasson Lars   Gall Mari-Anne   Spinas Giatgen A.  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.20, Iss.1, 2004-08, pp. : 41-51

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 6, 2015-06 ,pp. : 581-590

John Wiley & Sons Inc

Access to resources Recommend Favorite

The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus

By  

DIABETIC MEDICINE, Vol. 32, Iss. 7, 2015-07 ,pp. : 890-898

John Wiley & Sons Inc

Access to resources Recommend Favorite

Study comparing the effect of pioglitazone in combination with either metformin or sulphonylureas on lipid profile and glycaemic control in patients with type 2 diabetes (ECLA)

By Karamanos B.   Thanopoulou A.   Drossinos V.   Charalampidou E.   Sourmeli S.   Archimandritis A.    

Current Medical Research and Opinion, Vol. 27, Iss. 2, 2011-02 ,pp. : 303-313

Informa Healthcare

Access to resources Recommend Favorite

Peri‐operative continuation of metformin does not improve glycaemic control in patients with type 2 diabetes: A randomized controlled trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 3, 2018-03 ,pp. : 749-752

John Wiley & Sons Inc

Access to resources Recommend Favorite

Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 1462-8902, Iss. 10, 2015-10 ,pp. : 956-964

John Wiley & Sons Inc

Access to resources Recommend Favorite